NCT06880523 2025-12-18
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT06290505 2025-07-23
PALEO
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT06094140 2024-12-03
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03101475 2022-05-31
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03102047 2022-04-20
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
NSABP Foundation Inc
Phase 2 Completed